Access to estrogen patches can vary from one pharmacy to another. A Chelsea pharmacy that normally keeps a steady rotation on its shelves now has enough stock for only about six patients at a time, depending on how many patches each person needs. Women dealing with menopause have reported rationing doses or contacting multiple pharmacies to avoid running out.
The access problems have been building for months, according to CBS New York, which reported that patients across the country are taking extra steps to fill prescriptions. Andrea Weiss told the station that her pharmacy cut her supply from three months to one, then informed her in April that patches were unavailable, with no clear restocking timeline. Weiss said medical conditions make the patch her best option.
The same report said Rachelle Kuramoto, who lives in New York City, crossed state lines to obtain patches and was concerned about whether her pharmacy in Atlanta would continue carrying them. Abby Fazio, pharmacist and owner of New London Pharmacy in Chelsea, said her shop faces daily challenges securing enough prescriptions to serve its regular customers.
Why Demand Is Outpacing Reliable Access
Estrogen patches contain estradiol, used in hormone-replacement therapy to manage menopause symptoms and support healthy aging, as CBS News Baltimore has reported. The patches treat hot flashes, night sweats, mood changes and other symptoms, and are credited with protecting bone health, since the medication is delivered through the skin, bypassing the liver, and is processed more easily by the body than some alternatives, per CBS New York's reporting.
Demand took off after the Food and Drug Administration approved the removal of the black-box safety warning on estrogen therapy products in February 2026, a decision the agency itself has said drove more women toward the treatment. Prescriptions for estrogen patches numbered nearly 600,000 in 2024 before climbing to 1.6 million by May 2026, according to figures cited by CBS News. Separate data reviewed by CNBC found prescriptions rose 162% over two years, while Reuters reported Truveta tracked a 184% jump in patch use since 2023 — the sharpest increase among hormone-therapy types it studied.
FDA Says Patches Remain Available, Though Access Can Vary
The FDA has maintained that estrogen patches are not in shortage, even as patients and pharmacies report difficulty obtaining particular products. The agency has said it is aware of access problems linked to increased demand and is working with all six manufacturers to boost supply. In September, the Democratic Women's Caucus acknowledged a spike in prescriptions and strain on patch production, calling on the FDA to address what it described as a shortage.
What the FDA's Labeling Change Means
The FDA said its first batch of approved menopause-hormone labeling changes covered six products across four therapy categories; the initial action did not change every product label at once. The existing reporting describes the removal of a boxed warning, but that initial batch does not establish that all product labels changed or that all risks and warnings were removed. As of its September 3, 2026, update, the FDA said estradiol patches remained available, although availability of particular products or brands could vary by pharmacy or location. For patients who cannot obtain their usual patch, the agency advises contacting a healthcare provider and not stopping or changing medication without discussing it with them, according to the FDA and its availability update.
Medical providers say patch production simply is not keeping pace with demand. Dr. Sarah Berg, an OB-GYN and menopause-certified practitioner, called the situation frustrating and said the shortage is especially dire for women who had finally found a medication that relieved painful symptoms, only to lose reliable access to it.
Manufacturers Racing to Catch Up
Viatris, one of the companies that produces estrogen patches, said significantly increased demand led it to take steps to raise production, including adding a shift at its Vermont facility to run around-the-clock. Bayer, another manufacturer, expects periodic supply shortages of its Climara estrogen patch to continue until at least early 2027. Nationally, the American Society of Health-System Pharmacists has flagged the issue on its shortage database, though reports vary on the exact scope — CBS News described more than a dozen estradiol patch products listed, CNBC reported three types facing shortages, and USA Today put the number at almost 20 formulations affected.
For women unable to find patches, Dr. Berg said safe alternatives include gels, creams and an oral pill, though she warned some women may need months to adjust to a different form of treatment. Doctors have also cautioned that abruptly stopping patch use can cause symptoms to return, while switching brands may introduce new side effects — a risk that leaves patients like Weiss and Kuramoto weighing imperfect options while the supply chain tries to catch up.
